- EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
-
Won Hwangbo, Jeong Hyeon Lee, Sangjeong Ahn, Seojin Kim, Kyong Hwa Park, Chul Hwan Kim, Insun Kim
-
Korean J Pathol. 2013;47(2):107-115. Published online April 24, 2013
-
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.107
-
-
12,616
View
-
81
Download
-
15
Crossref
-
 Abstract
 PDF
- Background
The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment. MethodsA total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. ResultsEGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6- (CK5/6-) group, 11.2% of the HER-2-, EGFR+, CK5/6- group, and 19.1% of the HER-2-, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki-67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. ConclusionsEGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.
-
Citations
Citations to this article as recorded by  - An overview of phenylsulfonylfuroxan-based nitric oxide donors for cancer treatment
Chao Gao, Xingyu Li, Tong Liu, Wanning Wang, Jianhui Wu
Bioorganic Chemistry.2025; 154: 108020. CrossRef - Identification of a cross-talk between EGFR and Wnt/beta-catenin signaling pathways in HepG2 liver cancer cells
Gurjinder Singh, Md Mehedi Hossain, Aadil Qadir Bhat, Mir Owais Ayaz, Nasima Bano, Rafiqa Eachkoti, Mohd Jamal Dar
Cellular Signalling.2021; 79: 109885. CrossRef - Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
Shailendra K. Gautam, Ranjana K. Kanchan, Jawed A. Siddiqui, Shailendra K. Maurya, Sanchita Rauth, Naveenkumar Perumal, Pranita Atri, Ramakanth C. Venkata, Kavita Mallya, Sameer Mirza, Moorthy P. Ponnusamy, Vimla Band, Sidharth Mahapatra, Maneesh Jain, Su
Cancers.2020; 12(10): 2838. CrossRef - Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line
Mona A.M. Abo-Zeid, Mahmoud T. Abo-Elfadl, Amira M. Gamal-Eldeen
Environmental Toxicology and Pharmacology.2019; 71: 103207. CrossRef - Improved characterization of the relationship between long intergenic non‐coding RNA Linc00152 and the occurrence and development of malignancies
Jiasheng Xu, Jingjing Guo, Yangkai Jiang, Yujun Liu, Kaili Liao, Zhonghua Fu, Zhenfang Xiong
Cancer Medicine.2019; 8(10): 4722. CrossRef - Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome
Ge Yan, Mohamed E.M. Saeed, Sebastian Foersch, Jose Schneider, Wilfried Roth, Thomas Efferth
Oncotarget.2019; 10(20): 1918. CrossRef - A novel matrine derivative WM622 inhibits hepatocellular carcinoma by inhibiting PI3K/AKT signaling pathways
Xiao Sun, Xiao-bin Zhuo, Yi-ping Hu, Xuan Zheng, Qing-jie Zhao
Molecular and Cellular Biochemistry.2018; 449(1-2): 47. CrossRef - lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway
Yan Zhang, Cheng Xiang, Yuling Wang, Yuanyuan Duan, Ci Liu, Yongli Jin, Yajing Zhang
Biomedicine & Pharmacotherapy.2017; 94: 644. CrossRef - Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
Areej Fatima, Fomaz Tariq, Muhammad Faraz Arshad Malik, Muhammad Qasim, Farhan Haq
Journal of Breast Cancer.2017; 20(3): 246. CrossRef - Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
Malgorzata Banys-Paluchowski, Isabell Witzel, Sabine Riethdorf, Brigitte Rack, Wolfgang Janni, Peter A. Fasching, Erich-Franz Solomayer, Bahriye Aktas, Sabine Kasimir-Bauer, Klaus Pantel, Tanja Fehm, Volkmar Müller
Scientific Reports.2017;[Epub] CrossRef - EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib
James P. De Andrade, Jung M. Park, Vivian W. Gu, George W. Woodfield, Mikhail V. Kulak, Allison W. Lorenzen, Vincent T. Wu, Sarah E. Van Dorin, Philip M. Spanheimer, Ronald J. Weigel
Molecular Cancer Therapeutics.2016; 15(3): 503. CrossRef - Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
H J Lee, A N Seo, E J Kim, M H Jang, Y J Kim, J H Kim, S-W Kim, H S Ryu, I A Park, S-A Im, G Gong, K H Jung, H J Kim, S Y Park
British Journal of Cancer.2015; 112(1): 103. CrossRef - Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma
GANG LIN, XIAO-JIANG SUN, QIAN-BO HAN, ZHUN WANG, YA-PING XU, JIA-LEI GU, WEI WU, GU ZHANG, JIN-LIN HU, WEN-YONG SUN, WEI-MIN MAO
Oncology Letters.2015; 10(2): 901. CrossRef - Immunohistochemical Classification of Primary and Secondary Glioblastomas
Kyu Sang Lee, Gheeyoung Choe, Kyung Han Nam, An Na Seo, Sumi Yun, Kyung Ju Kim, Hwa Jin Cho, Sung Hye Park
Korean Journal of Pathology.2013; 47(6): 541. CrossRef - A Comparison of Tumor Biology in Primary Ductal CarcinomaIn SituRecurring as Invasive Carcinoma versus a NewIn Situ
Wenjing Zhou, Christine Johansson, Karin Jirström, Anita Ringberg, Carl Blomqvist, Rose-Marie Amini, Marie-Louise Fjallskog, Fredrik Wärnberg
International Journal of Breast Cancer.2013; 2013: 1. CrossRef
|
E-submission
